Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis.

Emily HenkleJeffrey R CurtisLang ChenBenjamin ChanTimothy R AksamitCharles L DaleyDavid E GriffithKevin L Winthrop

Published in: The European respiratory journal (2019)

Among patients with bronchiectasis, the use of ICSs was associated with an increased risk of hospitalised respiratory infections compared with macrolide monotherapy.

Keyphrases

cystic fibrosis
combination therapy
human health
open label
respiratory tract
risk assessment